4D Molecular Therapeutics, Inc. Stock price
Equities
FDMT
US35104E1001
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.32 USD | -9.90% | -3.61% | +60.81% |
Financials (USD)
Sales 2024 * | 6.35M | Sales 2025 * | 7.38M | Capitalization | 1.79B |
---|---|---|---|---|---|
Net income 2024 * | -153M | Net income 2025 * | -186M | EV / Sales 2024 * | 205 x |
Net cash position 2024 * | 482M | Net cash position 2025 * | 321M | EV / Sales 2025 * | 198 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-10.5
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.06% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | +5.35% | ||
1 week | +7.07% | ||
Current month | +28.02% | ||
1 month | +19.93% | ||
3 months | +70.00% | ||
6 months | +175.50% | ||
Current year | +77.05% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | - | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 17 M€ | -0.46% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 32.53 | -9.31% | 851 345 |
24-03-27 | 35.87 | +5.35% | 723,668 |
24-03-26 | 34.05 | +1.34% | 487,821 |
24-03-25 | 33.6 | 0.00% | 297,482 |
24-03-22 | 33.6 | -0.59% | 302,108 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.05% | 1.79B | |
+9.16% | 45.97B | |
+53.80% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |